Abstract
Background:
Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a progressive multisystem disorder caused by pathogenic TTR variants. Aim of this study is to delineate the clinical and genetic feature of ATTRv-PN in China and to evaluate diagnostic strategies for earlier and accurate recognition.
Methods:
We investigated two genetically confirmed Chinese patients with ATTRv-PN through comprehensive assessments, including electrophysiology, sural nerve biopsy, autonomic testing, cardiac imaging, neuroimaging, and cerebrospinal fluid analysis. Additionally, logistic regression was performed on 70 reported p.Val50Met cases to examine the relationship between age at onset and amyloid detection in sural nerve biopsies.
Results:
The two patients carried the p.Val50Met and p.Glu74Gly variants in the TTR gene, respectively. Both presented with distal paresthesia as the initial symptom and exhibited length-dependent, axonal-predominant sensorimotor polyneuropathy. Autonomic manifestations included alternating diarrhea/constipation and post-exertional hyperhidrosis. Subclinical cardiac abnormalities were identified, encompassing elevated biomarker of early cardiac strain, valvular regurgitation, left ventricular hypertrophy, and late gadolinium enhancement. In patient 1, sural nerve pathology showed marked loss of myelinated and unmyelinated fibers with perivascular lymphocytic infiltration but no amyloid deposition. Logistic regression revealed no significant association between age at onset and biopsy amyloid positivity (p = 0.91).
Conclusion:
This study expands the clinical and genetic landscape of ATTRv-PN in China and highlighted the heterogeneity of amyloid detection in nerve biopsies. Accurate and timely diagnosis requires an integrated approach combining clinical, electrophysiological, pathological, genetic, and multimodal imaging assessments to facilitate early initiation of disease-modifying therapies.
1 Introduction
Hereditary transthyretin amyloidosis (ATTRv) is a progressive, multisystem disorder caused by pathogenic variants in the transthyretin (TTR) gene. Mutant TTR destabilizes the transthyretin tetramer, leading to misfolding, amyloid fibril formation, and deposition in the peripheral nerves, heart, and other organs (). Among the spectrum of clinical manifestations, polyneuropathy (ATTRv-PN) is the most common and often the initial presentation, typically manifesting as length-dependent sensory-motor neuropathy accompanied by autonomic dysfunction. To date, more than 140 pathogenic variants have been identified in this small, 147-amino-acid protein (NM_000371.4; http://amyloidosismutations.com/mut-attr.php), with p.Val50Met (historically p.Val30Met) representing the most prevalent. This variant was first reported in endemic regions of Sweden, Portugal, and Japan (; ; ), but has since been recognized worldwide.
Despite its autosomal dominant inheritance, ATTRv exhibits striking incomplete penetrance and marked heterogeneity in age at onset, complicating diagnosis and obscuring true disease prevalence. In early-onset p.Val50Met carriers, penetrance rises from 10% by age 40%–71% by age 90 in Swedish cohorts (). Late-onset phenotypes pose further diagnostic challenges, often resulting in delayed recognition. The interplay among carrier frequency, age at onset, and penetrance profoundly shapes the epidemiology of ATTRv, underscoring the importance of population-specific investigations.
Unlike the extensive investigations conducted in Japan, studies of ATTRv in China remain relatively limited. Here, we report two Chinese patients with genetically confirmed ATTRv-PN, providing detailed clinical and pathological characterization. By reviewing previously published cases with p.Val50Met, we explore the potential relationship between age at onset and the detectability of amyloid deposits, and we emphasize an integrated diagnostic strategy that combines clinical, genetic, and pathological data to enable earlier recognition in underdiagnosed populations.
2 Materials and methods
2.1 Genetic study
Genomic DNA was analyzed through PCR amplification and Sanger sequencing (Kangxu Medical Laboratory, Beijing, China) for all coding exons of the TTR gene.
2.2 Sural nerve pathology
A sural nerve biopsy was performed on patient 1, and portions of the specimen were fixed in 10% neutral-buffered formalin, paraffin-embedded, and sectioned for routine hematoxylin and eosin (H&E) staining. Congo red staining with polarized light microscopy was performed to detect amyloid deposits. Semithin sections prepared from resin-embedded tissue were stained with methylene blue to assess myelinated fiber density and morphology. Immunohistochemistry was conducted using antibodies against myelin basic protein (MBP, monoclonal) and neurofilament (NF, monoclonal). A polymer-based horseradish peroxidase system with diaminobenzidine (DAB) was used for visualization.
For ultrastructural evaluation, separate nerve tissue was fixed in 2.5% glutaraldehyde, post-fixed in 1% osmium tetroxide, and embedded in EPON resin. Ultrathin sections were stained with uranyl acetate and lead citrate and examined under a transmission electron microscope to assess axonal and myelin ultrastructure and amyloid fibrils.
2.3 Literature review of amyloid deposition in sural nerve of patients with the p.Val50Met variant
A systematic search of the PubMed database was performed to identify published English-language reports describing sural nerve biopsies in patients with FAP or TTR amyloidosis. Search terms included “familial amyloid polyneuropathy” OR “transthyretin amyloidosis” in combination with “sural nerve.” We included cases in which patients carried the p.Val50Met (formerly p.Val30Met) TTR variant and for which individual clinical and histopathological data were available. To assess whether age at onset predicted amyloid deposition in sural nerve biopsies, we performed a logistic regression analysis using RStudio (Build 496).
3 Results
3.1 Clinical summary
3.1.1 Patient 1
A 70-year-old male with no family history presented with a nine-month history of progressive sensory disturbances, beginning with numbness, coldness, and tingling paresthesia in the hands and distal lower extremities. Over time, he developed ascending stiffness from the ankles to the knees, followed by worsening gait impairment and alternating diarrhea and constipation. Neurological examination showed diminished pain sensation in the distal upper and lower extremities. Motor strength was preserved, and no cerebellar or cranial nerve abnormalities were noted. Cardiopulmonary and abdominal examinations were unremarkable.
Laboratory studies revealed elevated albumin level (58.8 g/L; normal range: 40∼55 g/L) and N-terminal pro-B-type natriuretic peptide (NT-proBNP, 530 pg/mL; normal range: <125 pg/mL), with otherwise unremarkable cardiac biomarkers (troponin I and myoglobin), serum immunoglobulins, urine protein electrophoresis, and cerebrospinal fluid (CSF) analysis. He had no history of diabetes mellitus. Echocardiography demonstrated mitral and tricuspid regurgitation, while abdominal ultrasound revealed mild hepatic parenchymal heterogeneity. Autonomic testing identified impaired vagal and adrenergic cardiovascular responses. Brain MRI showed lacunar infarcts in the bilateral basal ganglia and ischemic white matter lesions. Additionally, vascular studies showed diffuse intima-media thickening with bilateral atherosclerotic plaques and an intramuscular venous thrombosis in the left calf. Electrophysiological studies confirmed a length-dependent peripheral neuropathy with mixed axonal and demyelinating features, predominantly axonal.
3.1.2 Patient 2
A 31-year-old man (III-5) with a strong family history of ATTRv (grandfather, mother, aunt, uncle, and cousins) presented with progressive liver dysfunction following liver transplantation at age 29 (Figure 1). Six months prior to evaluation, he developed lower limb paresthesia, including numbness and activity-induced neuropathic pain, accompanied exercise-related weakness and post-exertional hyperhidrosis. Symptoms progressed without fever, cardiac complaints, or gastrointestinal disturbances. Neurological examination revealed preserved muscle strength, absent deep tendon reflexes in the lower extremities, and reduced pain sensation along the lateral and anterior aspects of both legs. Reflexes and strength in the upper limbs were normal. Cardiovascular, pulmonary, and abdominal examinations were unremarkable.
FIGURE 1
CSF analysis demonstrated markedly elevated protein (1,058.2 ng/L; normal range: 150.0∼450.0 ng/L) with otherwise normal parameters. Cardiac evaluation revealed concentric left ventricular hypertrophy with diastolic dysfunction on echocardiography. Cardiac MRI confirmed diffuse ventricular wall thickening, most prominent in basal and mid segments, with late gadolinium enhancement involving both ventricles and the right atrium. Abdominal ultrasonography, brain MRI, and ophthalmoscopic examination were normal.
Electrophysiological studies evolved over time: nerve conduction studies (NCS) at age 23 were normal, but at age 31 they revealed absent sensory potentials, reduced motor conduction velocities (MCV) in median nerves (35∼48 m/s) and ulnar nerves (40∼52 m/s), as well as diminished compound muscle action potentials (CMAP, 1.2∼1.8 mV). Tibial motor responses were unelicitable, consistent with a predominantly axonal sensorimotor neuropathy with secondary demyelinating features.
3.2 Genetic findings
In Patient 1, Sanger sequencing revealed a heterozygous missense variant in TTR exon 2, c.148G>A (p.Val50Met; NM_000371.4). This variant is present in the gnomAD database (v4.1.0; accessed June 2025) with an allele frequency of 92/1,614,098 overall and 2/44,886 among East Asian individuals.
In Patient 2, a heterozygous missense variant in TTR exon 3, c.221A>G (p.Glu74Gly; NM_000371.4), was identified. This variant is absent from population databases and segregates with disease in his affected cousins (III-1 and III-4), supporting its pathogenicity (Figure 1).
3.3 Sural nerve pathological findings (patient 1)
Histopathological analysis of the sural nerve revealed sparse perivascular lymphocytic infiltration around a single small vessel, without definitive evidence of vasculitis (H&E staining; Figures 2A,B). Semithin toluidine blue staining demonstrated a moderate reduction of both large and small myelinated fibers, with no myelin ovoids or onion bulb formations (Figure 2C). Congo red staining was negative for amyloid deposition (data not shown).
FIGURE 2
Immunohistochemistry for MBP and NF confirmed loss of myelinated fibers (Figures 2D,E). Electron microscopy (EM) revealed a marked reduction in both myelinated and unmyelinated fibers, focal thickening and lamellation of myelin sheaths, and mild axonal degeneration in a subset of fibers, without evidence of amyloid fibrils (Figure 2F).
3.4 Literature review of described patients with the p.Val50Met variant
We collected 70 patients with the p.Val50Met variant for whom individual age at onset and sural nerve biopsy histopathological data were available (; ; ; ; ; ; ; ; ; ). The cohort included 58 males and 12 females. Congo red staining was used in all cases, with or without adjunctive TTR immunohistochemistry. Amyloid deposits were detected in 51 patients. Based on age at symptom onset, 15 patients were classified as early-onset (<50 years) and 55 as late-onset (≥50 years) (Supplementary Table S1).
Logistic regression analysis revealed no significant association between onset age and amyloid detection (β = −0.0023, standard error = 0.020, p = 0.91), indicating that the likelihood of amyloid deposition was not dependent on the age at symptom onset (Figure 3).
FIGURE 3
4 Discussion
ATTRv-PN remains challenging to distinguish from other axonal or demyelinating neuropathies due to its heterogenous presentation. In this study, we report two Chinese patients who both present with paresthesia as the initial symptom. Electrophysiological studies demonstrated length-dependent, axonal-predominant sensorimotor polyneuropathy, consistent with typical ATTRv-PN. Genetic analysis identified pathogenic TTR variants in both patients: p.Val50Met in patient 1, the most prevalent variant globally, including in China, and p.Glu74Gly in patient 2, the third most frequently detected TTR variant in the Chinese population ().
Autonomic dysfunction is a common and often disabling feature of ATTRv-PN. In patient 1, clinical manifestations included alternating diarrhea and constipation, and autonomic testing demonstrated impaired vagal and adrenergic cardiovascular responses, consistent with autonomic neuropathy (). Patient 2 experienced post-exertional hyperhidrosis, illustrating the variability of autonomic manifestations. Early recognition and proactive management of autonomic symptoms are essential to improve quality of life and prognosis in ATTRv-PN.
Beyond neuropathy, ATTR frequently involves the heart, with cardiomyopathy (ATTRv-CM) representing the leading cause of morbidity and mortality. Notably, neither of our two patients reported cardiac symptoms. Nevertheless, laboratory and imaging assessments revealed subclinical cardiac involvement. In patient 1, NT-proBNP was modestly elevated (530 pg/mL), suggesting early cardiac strain, a sensitive marker of myocardial involvement in systemic amyloidosis even in the absence of troponin or myoglobin elevation (). Echocardiography further demonstrated mitral and tricuspid regurgitation, potentially reflecting amyloid infiltration of the valvular apparatus or secondary hemodynamic alterations. Patient 2 exhibited more pronounced involvement, with concentric left ventricular hypertrophy and diastolic dysfunction on echocardiography, confirmed by cardiac MRI showing diffuse ventricular thickening and late gadolinium enhancement of both ventricles and the right atrium, hallmarks of amyloid cardiomyopathy (; ).
However, ATTR-specific cardiac confirmation using 99mTechnetium-pyrophosphate (99mTc-PYP) scintigraphy or endomyocardial biopsy was not performed, which limits definitive etiological attribution of the observed cardiac findings. Given evidence from recent family screening studies demonstrating that PYP scintigraphy can identify ATTRv-CM even in the absence of left ventricular hypertrophy (), the extent of ATTR-specific myocardial deposition may have been underestimated. These observations nonetheless highlight that cardiac involvement in ATTRv-PN may be clinically silent yet detectable by sensitive biomarkers and multimodal imaging reinforcing the need for systematic amyloid-specific cardiovascular evaluation.
Vascular involvement may also complicate ATTRv-PN. Neuroimaging of patient 1 revealed lacunar infarcts in the basal ganglia and ischemic white matter lesions, consistent with small-vessel cerebrovascular disease. Although ATTRv is not classically linked to ischemic stroke, these findings may reflect amyloid-related vasculopathy or coexisting vascular risk factors. Vascular ultrasound further demonstrated diffuse intima-media thickening and bilateral atherosclerotic plaques, indicative of systemic vasculopathy, and the presence of intramuscular venous thrombosis in the calf further highlights the vascular vulnerability. In patient 2, the markedly elevated CSF protein (1,058.2 ng/L) with otherwise normal parameters suggests a disruption of the blood-CSF barrier, a finding that could be misinterpreted as chronic inflammatory demyelinating polyneuropathy (CIDP), but is increasingly recognized in ATTRv ().
In patient 1, who carried the p.Val50Met variant, sural nerve biopsy did not reveal amyloid deposition on Congo red staining or electron microscopy. The sensitivity of amyloid detection in nerve tissue varies considerably across cohorts. In Japanese series of p.Val50Met ATTRv-PN, amyloid deposits were detected in 18/20 late-onset patients () and 15/19 mixed-onset cases (), with frequencies comparable to European reports, including 87.5% in Italy (21/24) and 86% in Portugal (; ). By contrast, in a Chinese series, Congo red positivity was observed in only 40% of sural nerve samples overall, with higher rates in early-onset (55.6%) compared with late-onset cases (27.3%); among patients with p.Val50Met, only 30% (3/10; 1 early-onset, 9 late-onset) were positive (). Taken together, these data suggest that age at onset may affect the likelihood of detecting amyloid deposits in nerve tissue.
We therefore reviewed reported p.Val50Met patients with available data on both age at onset and sural nerve amyloid deposition, and performed a logistic regression analysis, including 15 early-onset and 55 late-onset cases. The analysis showed no significant association between age at symptom onset and amyloid detection (p = 0.91). However, because this analysis was based on published literature data, it is subject to inherent limitations, including publication bias and heterogeneity in study design, reporting practices, and biopsy methodologies, and should therefore be interpreted with caution.
Notably, early- and late-onset ATTRv-PN differ in amyloid fibril composition, with early-onset cases exhibiting thick, full-length TTR fibrils and strong Congo red affinity, whereas late-onset cases often harbor thinner, fragmented fibrils with weaker congophilia, which may reduce biopsy sensitivity (; ). Additional factors, including variability in staining procedures, inter-observer interpretation, and the patchy distribution of amyloid deposits, may also contribute to false-negative results. Collectively, these findings highlight the limitations of sural nerve biopsy as a diagnostic tool and underscore the need for larger cohorts and standardized detection protocols to better clarify the relationship between disease onset age, fibril characteristics, and amyloid deposition rates.
In patient 1, sural nerve biopsy revealed perivascular lymphocytic infiltration around a small vessel, a finding that, although uncommon, has been reported in other ATTRv-PN cases. Similar inflammatory changes have been observed in sural nerves from multiple patients, indicating that lymphocytic infiltration can be part of the pathological spectrum of ATTRv-PN (). Beyond local nerve pathology, systemic immune alterations have also been described, including dysregulation of circulating cytokines such as interferon (IFN)-γ, IFN-α, IL-6, IL-7, and IL-33 during disease progression (). Collectively, these findings suggest that, while ATTRv-PN is classically regarded as a non-inflammatory neuropathy, neuroinflammatory mechanisms may contribute to disease heterogeneity and progression, with potential implications for diagnosis and therapeutic strategies.
Current therapeutic strategies for ATTRv aim to prevent amyloid formation either by stabilizing the TTR tetramer or by reducing its production. Tafamidis, the first approved disease-modifying therapy for both ATTRv-PN and ATTRv-CM, selectively binds to the T4 site of TTR, stabilizing the tetramer and slows disease progression, with the greatest efficacy when initiated early (). In patients with ATTRv-CM, tafamidis significantly reduced mortality and cardiovascular hospitalizations, particularly in those treated at early stages of cardiac involvement (). Gene-silencing therapies, including the antisense oligonucleotide (inotersen) and the small interfering RNA (patisiran), suppress hepatic TTR production and have demonstrated clinical benefit in slowing neurological progression (; ; ). More recently, in vivo CRISPR-Cas9 gene editing has emerged as a potentially curative approach. NTLA-2001, delivered via lipid nanoparticles, induces permanent TTR gene disruption, achieving up to 95% reduction in serum TTR levels after a single infusion with an acceptable safety profile ().
The efficacy of these treatments for ATTRv is strongly dependent to disease stage, underscoring the critical importance of early diagnosis and longitudinal monitoring in asymptomatic carriers. The Transthyretin Amyloidosis Outcomes Survey (THAOS), a global observational study, reported that more than one-third of asymptomatic TTR variant carriers developed symptomatic ATTRv amyloidosis within a median of 2.2 years after enrollment (). Supporting these findings, a longitudinal study of 98 presumed asymptomatic carriers with normal baseline NCS found that 11% exhibited NCS deterioration over a median follow-up of 5 years (). Although nerve biopsy may be required to confirm neuropathic involvement, it is not essential for initiating treatment in patients with red-flag symptoms or in clinically typical cases, such as those described in the present study. When histopathological evaluation is indicated, skin biopsy can provide information comparable to nerve biopsy while carrying a lower risk of complications.
In ATTRv-PN, small fiber neuropathy often precedes large fiber involvement, reflecting the early susceptibility of unmyelinated and thinly myelinated fibers to amyloid toxicity (). Given this early neuropathic pattern, systematic assessment of small fibers using techniques such as skin biopsy, quantitative sensory testing, and corneal confocal microscopy is essential for detecting pathological changes. In parallel, the development and validation of pre-symptomatic biomarkers, like the circulating TTR monomers and serum glial fibrillary acidic protein (sGFAP), offering potential avenues identify early disease and guide timely therapeutic intervention (; ).
5 Conclusion
The early and accurate diagnosis of ATTRv relies on a comprehensive, integrated approach encompassing clinical assessment, laboratory evaluation, genetic analysis, and pathological confirmation. Genetic testing of the TTR gene remains the standard for identifying pathogenic variants and at-risk family members. In ATTRv-PN patients, nerve biopsy demonstrating amyloid deposits provides definitive pathological evidence, although sensitivity may vary with disease stage, ancestry, and specific TTR variant. By periodically integrating these complementary diagnostic strategies, clinicians can accurately determine disease stage, enabling the timely initiation of disease-modifying therapies when they are most effective ultimately improving patient outcomes.
Statements
Data availability statement
The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by the Institutional Review Boards of the First Hospital of Hebei Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
XY: Conceptualization, Investigation, Methodology, Validation, Writing – original draft. YL: Data curation, Formal Analysis, Methodology, Software, Writing – original draft. XW: Formal Analysis, Investigation, Validation, Visualization, Writing – review and editing. BH: Data curation, Investigation, Project administration, Resources, Writing – review and editing. BX: Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This research is supported by the Hebei Youth Natural Science Foundation (H2020206163) and the Key Scientific and Technological Research Program of Hebei Health Commission (20200122).
Acknowledgments
The authors gratefully thank all study participants and their relatives for their invaluable contributions.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2026.1715134/full#supplementary-material
References
1
AdamsD.Gonzalez-DuarteA.O'RiordanW. D.YangC. C.UedaM.KristenA. V.et al (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med.379, 11–21. 10.1056/NEJMoa1716153
2
AdamsD.AndoY.BeiraoJ. M.CoelhoT.GertzM. A.GillmoreJ. D.et al (2021). Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J. Neurol.268, 2109–2122. 10.1007/s00415-019-09688-0
3
BarrosoF. A.CoelhoT.DispenzieriA.ConceicaoI.Waddington-CruzM.WixnerJ.et al (2022). Characteristics of patients with autonomic dysfunction in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid29, 175–183. 10.1080/13506129.2022.2043270
4
Bekircan-KurtC. E.GunesN.YilmazA.Erdem-OzdamarS.TanE. (2015). Three Turkish families with different transthyretin mutations. Neuromuscul. Disord.25, 686–692. 10.1016/j.nmd.2015.05.010
5
BensonM. D.Waddington-CruzM.BerkJ. L.PolydefkisM.DyckP. J.WangA. K.et al (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. N. Engl. J. Med.379, 22–31. 10.1056/NEJMoa1716793
6
CappellariM.CavallaroT.FerrariniM.CabriniI.TaioliF.FerrariS.et al (2011). Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J. Peripher Nerv. Syst.16, 119–129. 10.1111/j.1529-8027.2011.00331.x
7
CarrollA.DyckP. J.de CarvalhoM.KennersonM.ReillyM. M.KiernanM. C.et al (2022). Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J. Neurol. Neurosurg. Psychiatry93, 668–678. 10.1136/jnnp-2021-327909
8
ChaoC. C.YangW. K.YehT. Y.KanY. Y.WangY. S.LeeK. J.et al (2025). Transthyretin variants impact blood-nerve barrier and neuroinflammation in amyloidotic neuropathy. Brain148, 2537–2550. 10.1093/brain/awaf028
9
ChuX.KangJ.XuJ.JiangH.WuZ. Y.WangQ.et al (2025). A multicenter study of hereditary transthyretin amyloidosis in China. Ann. Neurol.97, 1158–1167. 10.1002/ana.27203
10
CoelhoT.YarlasA.Waddington-CruzM.WhiteM. K.Sikora KesslerA.LovleyA.et al (2020). Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. J. Neurol.267, 1070–1079. 10.1007/s00415-019-09671-9
11
CoelhoT.ConceicaoI.Waddington-CruzM.KeohaneD.SultanM. B.ChapmanD.et al (2022). A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the transthyretin amyloidosis outcomes survey (THAOS). Amyloid29, 228–236. 10.1080/13506129.2022.2070470
12
Costa-RodriguesD.LeiteJ. P.SaraivaM. J.AlmeidaM. R.GalesL. (2024). Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis. Amyloid31, 202–208. 10.1080/13506129.2024.2368860
13
DuK.LiF.WangH.MiaoY.LvH.ZhangW.et al (2021). Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study. Ann. Clin. Transl. Neurol.8, 831–841. 10.1002/acn3.51328
14
FernandesA.CoelhoT.RodriguesA.FelgueirasH.OliveiraP.GuimaraesA.et al (2019). Clinicopathological correlations of sural nerve biopsies in TTR Val30Met familial amyloid polyneuropathy. Brain Commun.1, fcz032. 10.1093/braincomms/fcz032
15
GillmoreJ. D.GaneE.TaubelJ.KaoJ.FontanaM.MaitlandM. L.et al (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med.385, 493–502. 10.1056/NEJMoa2107454
16
GorramF.OlssonM.AlarconF.NuelG.AnanI.Plante-BordeneuveV. (2021). New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid28, 84–90. 10.1080/13506129.2020.1841623
17
HolmgrenG.HolmbergE.LindstromA.LindstromE.NordensonI.SandgrenO.et al (1988). Diagnosis of familial amyloidotic polyneuropathy in Sweden by RFLP analysis. Clin. Genet.33, 176–180. 10.1111/j.1399-0004.1988.tb03434.x
18
IhseE.YboA.SuhrO.LindqvistP.BackmanC.WestermarkP. (2008). Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J. Pathol.216, 253–261. 10.1002/path.2411
19
IkedaS.NakazatoM.AndoY.SobueG. (2002). Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology58 (58), 1001–1007. 10.1212/wnl.58.7.1001
20
KoikeH.SobueG. (2012). Late-onset familial amyloid polyneuropathy in Japan. Amyloid19 (Suppl. 1), 55–57. 10.3109/13506129.2012.674580
21
KoikeH.MisuK.SugiuraM.IijimaM.MoriK.YamamotoM.et al (2004). Pathology of early-vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology63, 129–138. 10.1212/01.wnl.0000132966.36437.12
22
KoikeH.HashimotoR.TomitaM.KawagashiraY.IijimaM.TanakaF.et al (2011). Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid18, 53–62. 10.3109/13506129.2011.565524
23
KoikeH.NishiR.IkedaS.KawagashiraY.IijimaM.SakuraiT.et al (2018). The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: an ultrastructural study. J. Neurol. Sci.394, 99–106. 10.1016/j.jns.2018.09.011
24
KollmerJ.SahmF.HegenbartU.PurruckerJ. C.KimmichC.SchonlandS. O.et al (2017). Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology89, 475–484. 10.1212/WNL.0000000000004178
25
LuigettiM.RomozziM.BisogniG.CardelliniD.CavallaroT.Di PaolantonioA.et al (2020). hATTR pathology: nerve biopsy results from Italian referral centers. Brain Sci.10, 10. 10.3390/brainsci10110780
26
MathisS.MagyL.DialloL.BoukhrisS.VallatJ. M. (2012). Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve45, 26–31. 10.1002/mus.22229
27
MaurerM. S.SchwartzJ. H.GundapaneniB.ElliottP. M.MerliniG.Waddington-CruzM.et al (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med.379, 1007–1016. 10.1056/NEJMoa1805689
28
MengL. C.LyuH.ZhangW.LiuJ.WangZ. X.YuanY. (2015). Hereditary transthyretin amyloidosis in eight Chinese families. Chin. Med. J. Engl.128, 2902–2905. 10.4103/0366-6999.168048
29
MisuK.HattoriN.NagamatsuM.IkedaS.AndoY.NakazatoM.et al (1999). Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain122 (10), 1951–1962. 10.1093/brain/122.10.1951
30
MohseniA.ZandiehG.PorterK.PozzessereC.WagleA.BorhaniA.et al (2025). Cardiac amyloidosis: a comprehensive review of imaging findings. Acad. Radiol.32, 2517–2528. 10.1016/j.acra.2025.01.022
31
MullerS. A.Peiró-AventinB.BiagioniG.TiniG.SaturiG.KronbergerC.et al (2024). Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis. Eur. J. Heart Fail26, 2025–2034. 10.1002/ejhf.3339
32
PerfettoF.ZampieriM.FumagalliC.AllinoviM.CappelliF. (2022). Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Intern Emerg. Med.17, 957–969. 10.1007/s11739-022-02958-2
33
PlantoneD.PrimianoG.RighiD.RomanoA.LuigettiM.De StefanoN. (2023). Current evidence supporting the role of immune response in ATTRv amyloidosis. Cells12, 12. 10.3390/cells12192383
34
PlantoneD.LuigettiM.MancoC.RomanoA.LeonardiL.GuglielminoV.et al (2025). Elevated serum concentrations of GFAP in hereditary transthyretin amyloidosis since pre-symptomatic stages. J. Neurol.272, 340. 10.1007/s00415-025-13072-6
35
ScheelP. J.3rdMukherjeeM.HaysA. G.VaishnavJ. (2022). Multimodality imaging in the evaluation and prognostication of cardiac amyloidosis. Front. Cardiovasc Med.9, 787618. 10.3389/fcvm.2022.787618
36
SchulzN.BeauvaisD.CauquilC.LabeyrieC.IliescuI.FrancouB.et al (2025). Intracutaneous amyloid deposition is associated with nerve conduction studies deterioration in presumed asymptomatic pathogenic variant TTR carriers. Eur. J. Neurol.32, e70277. 10.1111/ene.70277
37
SousaA.CoelhoT.BarrosJ.SequeirosJ. (1995). Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in povoa do varzim and vila do conde (north of Portugal). Am. J. Med. Genet.60, 512–521. 10.1002/ajmg.1320600606
38
YoshiokaA.YamayaY.SaikiS.HiroseG.ShimazakiK.NakamuraM.et al (2001). A case of familial amyloid polyneuropathy homozygous for the transthyretin Val30Met gene with motor-dominant sensorimotor polyneuropathy and unusual sural nerve pathological findings. Arch. Neurol.58, 1914–1918. 10.1001/archneur.58.11.1914
Summary
Keywords
ATTRv-PN, hereditary transthyretin amyloidosis, polyneuropathy, sural nerve biopsy, TTR
Citation
Yuan X, Lv Y, Wang X, Han B and Xie B (2026) Clinical and genetic features of hereditary transthyretin amyloidosis with polyneuropathy in China: insights from case analysis and literature review. Front. Genet. 17:1715134. doi: 10.3389/fgene.2026.1715134
Received
07 October 2025
Revised
08 January 2026
Accepted
10 February 2026
Published
19 February 2026
Volume
17 - 2026
Edited by
Xuan He, Peking University Third Hospital, China
Reviewed by
Steven Muller, University Medical Center Utrecht, Netherlands
Esteban Calabrese, Hospital Español, Argentina
Updates
Copyright
© 2026 Yuan, Lv, Wang, Han and Xie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bingchuan Xie, xbc150908@gmail.com
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.